Article Text

Download PDFPDF
Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives
  1. D. LORUSSO*,
  4. L. MARINI,
  5. V. ADAMO§ and
  6. G. SCAMBIA*
  1. *Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Italy
  2. Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy
  3. Medical Department, Eli Lilly, Florence, Italy
  4. §Oncology Unit, University of Messina, Messina, Italy
  1. Address correspondence and reprint requests to: Giovanni Scambia, MD, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Largo A. Gemelli, 8 00168 Rome, Italy. Email: giovanni.scambia{at}


Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown consistent activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogs, gemcitabine has been combined with carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of gemcitabine and other agents, including paclitaxel, is also feasible and has been actively studied in order to establish the role of gemcitabine in the management of treated and untreated ovarian cancer patients.

  • gemcitabine
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.